疼痛管理薬およびデバイスの世界市場

世界の疼痛管理薬およびデバイスの市場規模は、2023年の846億米ドルから、予測期間中は5.4%のCAGRで推移し、2028年末には1,099億米ドルの規模に成長すると予測されています。

製品別では、医薬品の部門が2023年の779億米ドルから、同期間中5.3%のCAGRで推移し、2028年末には1,006億米ドルの規模に成長すると予測されています。また、デバイスの部門は2023年の67億米ドルから、6.7%のCAGRで推移し、2028年には92億米ドルの規模に成長すると予測されています。

当レポートでは、世界の疼痛管理薬およびデバイスの市場を調査し、市場および技術の概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術および特許の動向、臨床試験の動向、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

• 市場の見通し
• 疼痛管理薬およびデバイス市場のハイライト

第3章 市場概要

• 疼痛の歴史と疼痛の治療
• 疼痛の認識
• 疼痛のタイプ
• 急性疼痛
• 慢性疼痛
• 疼痛の評価
• 主観的
• 客観的
• 疼痛の診断法
• 疼痛の治療法
• 身体的疼痛の治療モダリティ
• 鍼治療・指圧
• アイシング（凍結療法）
• 関節モビライゼーション
• 手技
• マッサージ
• けん引
• 放射線治療
• 高周波神経アブレーションと硬膜外鏡検査
• 手術
• ジャグジーバス（温熱療法）
• 心理疼痛療法
• バイオフィードバック
• 催眠
• 行動修正/オペラント条件付け
• リラクゼーション・ストレス管理トレーニング
• 画像
• 自律訓練法
• 心理社会的介入
• ディストラクション・リフレーミング

第4章 市場力学

• 概要
• 市場促進要因
• 市場抑制要因
• 市場の課題

第5章 市場内訳：製品別

• 市場概要
• 市場シェア・予測
• 医薬品
• 麻薬
• 非麻薬
• 抗片頭痛薬
• 麻酔薬
• その他
• 疼痛管理デバイス
• 神経刺激デバイス
• 輸液ポンプ
• アブレーションデバイス

第6章 市場内訳：用途別

• 市場概要
• 市場シェア・予測
• 筋骨格疼痛
• 術後疼痛
• 神経因性疼痛
• 癌の疼痛
• 片頭痛
• その他
• HIV/エイズ
• 火傷
• 歯痛

第7章 市場内訳：地域別

• 市場概要
• 市場シェア予測
• 北米
• 米国
• カナダ
• 欧州
• ドイツ
• 英国
• イタリア
• フランス
• その他の欧州
• アジア太平洋
• 中国
• インド
• 日本
• その他のアジア太平洋地域
• その他の地域

第8章 ESGの展開

• ESGの概要
• 疼痛管理薬およびデバイス業界の持続可能性：ESGの観点
• ESGの主要な問題
• ESGランキング
• 疼痛管理薬およびデバイス市場におけるESGに対する消費者の意識
• ケーススタディ
• BCCによる総論

第9章 新興技術

• 概要
• オピオイド薬における技術の進歩
• 非麻薬における技術の進歩
• 神経調節デバイスにおける技術の進歩
• 輸液ポンプの技術の進歩
• 疼痛管理の動向
• 薬理ゲノミクス
• AIによる疼痛管理

第10章 臨床試験・特許分析

• 臨床試験の概要
• 臨床試験分析：研究タイプ別
• 臨床試験分析：ステータス別
• 臨床試験分析：フェーズ別
• 臨床試験分析：地域別
• 特許分析の概要
• 特許：年別
• 上位出願人の特許
• 上位特許保有者の特許
• 特許：管轄区域別

第11章 競合情報

• 市場分析
• 疼痛管理薬市場
• 疼痛管理デバイス市場
• 資金調達
• 最近の動向：主要企業別

第12章 企業プロファイル

• ABBOTT LABORATORIES
• ABBVIE INC
• ASSERTIO HOLDINGS INC.
• ASTRAZENECA PLC
• BOSTON SCIENTIFIC CORP.
• ELI LILLY & CO.
• ENDO INTERNATIONAL PLC
• ENOVIS CORP.
• GLAXOSMITHKLINE
• GRUNENTHAL GMBH
• JOHNSON & JOHNSON
• MEDTRONIC PLC
• NOVARTIS INTERNATIONAL AG
• VERTEX PHARMACEUTICALS INC.
• VIATRIS INC.

第13章 付録：頭字語

List of Tables

• Summary Table B : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Summary Table A : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 1 : Objective Signs of Pain
• Table 2 : Prevalence of Chronic Pain in Older Adults by Site
• Table 3 : Opioid Lawsuit Settlements
• Table 4 : Global Market for Pain Management Drugs and Devices , by Product, Through 2028
• Table 5 : FDA Pain Management Drug Approvals, 2020-2023
• Table 6 : Pain Management Major Drugs by Company
• Table 7 : Emerging Pain Therapeutics
• Table 8 : Global Market for Pain Management Pharmaceuticals, by Region, Through 2028
• Table 9 : Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
• Table 10 : Classification of Narcotic Analgesics Based on Chemical Structure
• Table 11 : Most Common Narcotic Analgesics
• Table 12 : Approved Labeling Describing Abuse-Deterrent Properties
• Table 13 : Global Market for Narcotic Drugs, by Region, Through 2028
• Table 14 : Global Market for Non-narcotic Drugs, by Region, Through 2028
• Table 15 : Global Market for Antimigraine Drugs, by Region, Through 2028
• Table 16 : Most Commonly Used General Anesthetic Agents
• Table 17 : Most Commonly Used Topical and Local Anesthetic Agents
• Table 18 : Global Market for Anesthesia Drugs, by Region, Through 2028
• Table 19 : Global Market for Other Drugs, by Region, Through 2028
• Table 20 : Global Market for Pain Management Devices, by Region, Through 2028
• Table 21 : Global Market for Pain Management Devices, by Type, Through 2028
• Table 22 : Spinal Cord Stimulation Systems By Major Companies
• Table 23 : TENS Devices by Major Companies
• Table 24 : Global Market for Neurostimulation Devices, by Region, Through 2028
• Table 25 : PCA Devices by Companies
• Table 26 : Global Market for Infusion Pumps, by Region, Through 2028
• Table 27 : Global Market for Ablation Devices, by Region, Through 2028
• Table 28 : Global Market for Pain Management Drugs and Devices, by Application, Through 2028
• Table 29 : Pharmacological Musculoskeletal Pain Management
• Table 30 : Global Market for Musculoskeletal Pain, by Region, Through 2028
• Table 31 : Pharmacological Post-operative Pain Management
• Table 32 : Cumulative Volumes of Hip and Knee Procedures, 2012-2021
• Table 33 : Global Market for Post-operative Pain, by Region, Through 2028
• Table 34 : Neuropathic Pain Medication
• Table 35 : Global Market for Neuropathic Pain, by Region, Through 2028
• Table 36 : Cancer Pain Medication
• Table 37 : Global Market for Cancer Pain, by Region, Through 2028
• Table 38 : Global Market for Migraine/Headache Pain, by Region, Through 2028
• Table 39 : Global Market for Other Pain Applications, by Region, Through 2028
• Table 40 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 41 : ESG Ranking of Major Pharma Players for Pain Therapeutics,2022
• Table 42 : ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
• Table 43 : ESG: Environmental Overview
• Table 44 : ESG: Social Overview
• Table 45 : ESG: Governance Overview
• Table 46 : Clinical Trials on Pain Management, by Type of Study, September 2023
• Table 47 : Clinical Trials on Pain Mangement, by Status, September 2023
• Table 48 : Clinical Trials on Pain Mangement, by Phase, September 2023
• Table 49 : Clinical Trials on Pain Mangement, by Region, September 2023
• Table 50 : Number of Patents by Top-Ranking Applicant, 2018-2022
• Table 51 : Number of Patents by Top-Ranking Patent Holder, 2018-2022
• Table 52 : Number of Patents, by Jurisdiction, 2018-2022
• Table 53 : Global Market Ranking in the Neuromodulation Segment, by Manufacturer, 2022
• Table 54 : Global Market Ranking in the Infusion Pumps Segment, by Manufacturer, 2022
• Table 55 : Recent Development, 2020-2023
• Table 56 : Abbott Laboratories: Financials, 2021 and 2022
• Table 57 : Abbott Laboratories: Product Portfolio
• Table 58 : Abbott Laboratories.: Key Developments, 2021-2022
• Table 59 : AbbVie Inc.: Financials, 2021 and 2022
• Table 60 : AbbVie Inc.: Key Developments, 2021 and 2022
• Table 61 : Assertio Holdings Inc.: Financials, 2021 and 2022
• Table 62 : Boston Scientific Corp.: Financials, 2021 and 2022
• Table 63 : Boston Scientific Corp.: Product Portfolio
• Table 64 : Eli Lily & Co.: Financials, 2021 and 2022
• Table 65 : Eli Lily & Co.: Key Developments, 2021-2023
• Table 66 : Endo International plc: Financials, 2021 and 2022
• Table 67 : Endo International plc: Key Developments, 2021-2023
• Table 68 : Enovis Corp.: Financials, 2021 and 2022
• Table 69 : GlaxoSmithKline: Financials, 2021 and 2022
• Table 70 : Grunenthal GmbH: Financials, 2021 and 2022
• Table 71 : Grunenthal GmbH: Key Developments, 2022
• Table 72 : Johnson & Johnson: Financials, 2021 and 2022
• Table 73 : Medtronic plc: Financials, 2021 and 2022
• Table 74 : Medtronic plc: Product Portfolio
• Table 75 : Medtronic plc: Key Developments, 2020-2023
• Table 76 : Novartis International AG: Financials, 2021 and 2022
• Table 77 : Vertex Pharmaceuticals Inc.: Key Developments, 2023
• Table 78 : Viatris Inc.: Financials, 2021 and 2022
• Table 79 : Acronyms Used in This Report

List of Figures

• Summary Figure A : Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
• Summary Figure B : Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
• Figure 1 : Pain Management Techniques
• Figure 2 : Pain Management Drugs and Devices: Market Dynamics
• Figure 3 : Common Chronic Pain: Reasons
• Figure 4 : Cancer Incidence, by Region, 2020 vs. 2040
• Figure 5 : Percentage of Global Population above 65 Years, 2018-2022
• Figure 6 : Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
• Figure 7 : Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
• Figure 8 : Proportion of the Individual Opioid Consumption in Morphine Milligram Equivalents (MME) by Country Income in 2009 vs. 2019
• Figure 9 : Total Number of Opioid Prescriptions Dispensed in the U.S., 2010-2020
• Figure 10 : Opioid Dispensing Rate per 100 Persons, U.S, 2010-2020
• Figure 11 : Global Market for Narcotic Drugs, by Region, 2020-2028
• Figure 12 : Number of Drug Overdose Deaths in the U.S., 2019-2021
• Figure 13 : Global Market for Non-narcotic Drugs, by Region, 2020-2028
• Figure 14 : Symptomatic Medication by Headache Severity
• Figure 15 : Preventive Drugs for Migraines
• Figure 16 : Global Market for Antimigraine Drugs, by Region, 2020-2028
• Figure 17 : Global Market for Anesthesia Drugs, by Region, 2020-2028
• Figure 18 : Global Market for Other Drugs, by Region, 2020-2028
• Figure 19 : Global Market Shares of Pain Management Devices, by Type, 2022
• Figure 20 : SCS Application for Pain Management
• Figure 21 : Global Market for Neurostimulation Devices, by Region, 2020-2028
• Figure 22 : Global Market for Infusion Pumps, by Region, 2020-2028
• Figure 23 : Global Market for Ablation Devices, by Region, 2020-2028
• Figure 24 : Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
• Figure 25 : Global Market for Musculoskeletal Pain, by Region, 2020-2028
• Figure 26 : Global Market for Post-operative Pain, by Region, 2020-2028
• Figure 27 : Classification of Neuropathic Pain
• Figure 28 : Global Market for Neuropathic Pain, by Region, 2020-2028
• Figure 29 : Causes of Cancer Pain
• Figure 30 : Global Market for Cancer Pain, by Region, 2020-2028
• Figure 31 : Global Market for Migraine/Headache Pain, by Region, 2020-2028
• Figure 32 : Burn Pain Management Approach
• Figure 33 : Burn Pain Management Approach
• Figure 34 : Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
• Figure 35 : North American Market for Pain Management, 2020-2028
• Figure 36 : European Market for Pain Management, 2020-2028
• Figure 37 : Asia-Pacific Market for Pain Management, 2020-2028
• Figure 38 : Rest of the World Market for Pain Management, 2020-2028
• Figure 39 : ESG Pillars
• Figure 40 : Advantages of ESG for Companies
• Figure 41 : ESG-Adoption Level across Industries
• Figure 42 : Hospitals: Sustainability Priorities
• Figure 43 : Novartis: ESG Rating
• Figure 44 : Novartis: Major ESG Activities, 2022
• Figure 45 : Number of Patents Granted, by Year, 2018-2022
• Figure 46 : Abbott Laboratories: Financials, 2021 and 2022
• Figure 47 : Abbott Laboratories: Revenue Shares, by Business Unit, 2022
• Figure 48 : Abbott Laboratories: Revenue Shares, by Region, 2022
• Figure 49 : AbbVie Inc.: Financials, 2021 and 2022
• Figure 50 : AbbVie Inc.: Revenue Shares, by Business Unit, 2022
• Figure 51 : AbbVie Inc.: Revenue Shares, by Region, 2022
• Figure 52 : Assertio Holdings Inc.: Financials, 2021 and 2022
• Figure 53 : Assertio Holdings Inc.: Revenue Shares, by Business Unit, 2022
• Figure 54 : Boston Scientific Corp.: Financial, 2021 and 2022
• Figure 55 : Boston Scientific Corp.: Revenue Shares, by Business Unit, 2022
• Figure 56 : Boston Scientific Corp.: Revenue Shares, by Country/Region, 2022
• Figure 57 : Eli Lily & Co.: Annual Revenue, 2021 and 2022
• Figure 58 : Eli Lily & Co.: Revenue Shares, by Business Unit, 2022
• Figure 59 : Eli Lily & Co.: Revenue Shares, by Region, 2022
• Figure 60 : Endo International plc: Financials, 2021 and 2022
• Figure 61 : Endo International plc: Revenue Shares, by Business Unit, 2022
• Figure 62 : Enovis Corp.: Financials, 2021 and 2022
• Figure 63 : Enovis Corp.: Revenue Shares, by Business Unit, 2022
• Figure 64 : Enovis Corp.: Revenue Shares, by Country/Region, 2022
• Figure 65 : GlaxoSmithKline: Financial, 2021 and 2022
• Figure 66 : GlaxoSmithKline: Revenue Shares, by Business Unit, 2022
• Figure 67 : GlaxoSmithKline: Revenue Shares, by Region, 2022
• Figure 68 : Grunenthal GmbH: Financials, 2021 and 2022
• Figure 69 : Grunenthal GmbH: Market Share, by Business Segment, 2022
• Figure 70 : Grunenthal GmbH: Market Share, by Region, 2022
• Figure 71 : Johnson & Johnson: Financials, 2021 and 2022
• Figure 72 : Johnson & Johnson: Revenue Shares, by Business Segment, 2022
• Figure 73 : Johnson & Johnson: Revenue Shares, by Country/Region, 2022
• Figure 74 : Medtronic plc: Financials, 2021 and 2022
• Figure 75 : Medtronic plc: Market Share, by Business Unit, 2022
• Figure 76 : Medtronic plc: Market Share, by Region, 2022
• Figure 77 : Novartis International AG: Financials, 2021 and 2022
• Figure 78 : Novartis International AG: Revenue Shares, by Business Unit, 2022
• Figure 79 : Novartis AG: Revenue Shares, by Region, 2022
• Figure 80 : Viatris Inc.: Financials, 2021 and 2022
• Figure 81 : Viatris Inc.: Revenue Shares, by Region, 2022

Highlights:

The global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2023-2028.

Pharmaceuticals market for pain management drugs and devices is expected to increase from $77.9 billion in 2023 to $100.6 billion by the end of 2028, with a CAGR of 5.3% during the forecast period of 2023-2028.

Medical devices market for pain management drugs and devices is expected to increase from $6.7 billion in 2023 to $9.2 billion by the end of 2028, with a CAGR of 6.7% during the forecast period of 2023-2028.

##img_0A##

Report Scope:

The current report provides detailed analysis of the market for pain management drugs and devices. It highlights the current and future market potential of pain management drugs and devices and gives a detailed analysis of the market's drivers, restraints and challenges. The report also covers market projections for 2028 and provides market rankings for key market players. It also covers the competitive environment and regulatory landscape, and it details the market share of pain management drugs and devices based on product and application. Based on products, the global pain management drugs and devices market is segmented into pharmaceuticals and medical devices. Based on applications, the market is segmented into post-operative pain, neuropathic pain, cancer pain, migraine/headache, musculoskeletal pain and other applications. The report includes company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments.

The market has been divided by geography into North America, Europe, Asia-Pacific and the Rest of the world. The North American region comprises countries such as the U.S. and Canada; Europe includes countries Germany, U.K., Italy, France and the Rest of Europe; Asia-Pacific includes countries China, India, Japan and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021, which serve as the historical years; 2022 is the base year; and forecast data is given for 2028.

Not covered in the report are drugs or devices that relieve pain by treating the specific condition or disorder. These include treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other similar diseases. Only those disease-specific treatments that involve a relief of the pain symptoms associated with the respective condition are included.

Here is a comparison of a treatment for a disease (in this case, rheumatoid arthritis) that naturally relieves symptoms vs. a treatment for the relief of the pain associated with the disease -

• Enbrel: Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
• Celebrex: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.

Report Includes:

• 44 data tables and 37 additional tables
• An overview of the global market for pain management drugs and devices
• Estimates of the market size and analyses of global market trends with data from 2020-2023, and projections of compound annual growth rates (CAGRs) through 2028
• Assessment of pain, history of pain and pain management, and information on physical pain treatment modalities and psychological pain therapies.
• Coverage of emerging technologies in the pain management market, an assessment of technology advances in opioid drugs, as well as in non-narcotic drugs, which has revolutionized pain management by providing practical alternatives to opioids.
• Assessment of factors driving the industry's growth, including market opportunities and restraints
• Examination of product categories, clinical trials, new regulatory requirements and relevant patents
• Coverage of market trends in undertreatment issues, professional issues, managed care pain issues, new therapies, product pipelines, generics, pain research and drug delivery
• Company profiles of major players within the industry, including Abbott Laboratories, AbbVie Inc., Assertio Holdings Inc., Grunenthal GmbH, and Johnson & Johnson

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in this Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Highlights of the Market for Pain Management Drugs and Devices

Chapter 3 Market Overview

• History of Pain and Pain Treatment
• The Perception of Pain
• Types of Pain
• Acute Pain
• Chronic Pain
• Assessment of Pain
• Subjective
• Objective
• How Pain is Diagnosed
• How Pain is Treated
• Physical Pain Treatment Modalities
• Acupuncture/Acupressure
• Ice (Cryotherapy)
• Joint Mobilization
• Manipulation
• Massage
• Traction
• Radiation Therapy
• Radio-Frequency Neuroablation and Epiduroscopy
• Surgery
• Whirlpool Bath (Thermotherapy)
• Psychological Pain Therapies
• Biofeedback
• Hypnosis
• Behavior Modification/Operant Conditioning
• Relaxation and Stress Management Training
• Imagery
• Autogenic Training
• Psychosocial Interventions
• Distraction and Reframing

Chapter 4 Market Dynamics

• Overview
• Market Drivers
• Market Restraints
• Market Challenges

Chapter 5 Market Breakdown by Product

• Market Overview
• Market Share and Forecast
• Pharmaceuticals
• Narcotic Drugs
• Non-narcotic Drugs
• Antimigraine Drugs
• Anesthesia Drugs
• Other Drugs
• Pain Management Devices
• Neurostimulation Devices
• Infusion Pumps
• Ablation Devices

Chapter 6 Market Breakdown by Application

• Market Overview
• Market Share and Forecast
• Musculoskeletal Pain
• Post-operative Pain
• Neuropathic Pain
• Cancer Pain
• Migraine/Headache
• Other Applications
• HIV/AIDS
• Burn Pain
• Dental Pain

Chapter 7 Market Breakdown by Region

• Market Overview
• Market Share Forecast
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• Italy
• France
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
• Rest of the World

Chapter 8 ESG Development

• Introduction to ESG
• Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
• Key ESG Issues
• ESG Ranking
• Consumer Attitudes toward ESG in the Market for Pain Management Drugs and Devices
• Case Study
• Concluding Remarks from BCC

Chapter 9 Emerging Technologies

• Overview
• Technology Advancements in Opioid Drugs
• Technology Advancements in Non-narcotic Drugs
• Technology Advancements in Neuromodulation Devices
• Technology Advancements in Infusion Pumps
• Trends in Pain Management
• Pharmacogenomics
• AI Pain Management

Chapter 10 Clinical Trials and Patent Analysis

• Overview of Clinical Trials
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Clinical Trials Analysis by Region
• Overview of Patent Analysis
• Patents by Year
• Patents by Top-Ranking Applicant
• Patents by Top-Ranking Patent Holder
• Patents by Jurisdiction

Chapter 11 Competitive Intelligence

• Market Analysis
• Market for Pain Management Drugs
• Market for Pain Management Medical Devices
• Funding
• Recent Developments by Key Market Players

Chapter 12 Company Profiles

• ABBOTT LABORATORIES
• ABBVIE INC
• ASSERTIO HOLDINGS INC.
• ASTRAZENECA PLC
• BOSTON SCIENTIFIC CORP.
• ELI LILLY & CO.
• ENDO INTERNATIONAL PLC
• ENOVIS CORP.
• GLAXOSMITHKLINE
• GRUNENTHAL GMBH
• JOHNSON & JOHNSON
• MEDTRONIC PLC
• NOVARTIS INTERNATIONAL AG
• VERTEX PHARMACEUTICALS INC.
• VIATRIS INC.

Chapter 13 Appendix: Acronyms